Author:
Ribes Immaculata,Poza Juan,Campos Ezequiel,Tunic Ignacio,Domingo Maria
Abstract
Background: A wide variety of contraceptive methods are available, some of them reimbursed by the Spanish National Health System (SNHS). However, the number of unintended pregnancies (UP) is still significant, leading to a high economic burden, mainly derived from non-adherence to and the incorrect use of contraceptive methods. Objectives: This study aims to estimate the economic burden associated with reversible contraception management in Spain, from the perspectives of both the SNHS and women, over a 5-year period. Methods: A survey was performed to identify contraception management in Spain based on the experience of a panel of six expert gynecologists. An economic model was conducted to quantify the current burden of contraception according to healthcare resources use over 5 years. The costs included in the analysis were diagnostic tests, initial and follow-up consultations, methods acquisition costs, and UP derived from therapy failure. Results: Reversible contraception costs in Spain amount to €12.5 billion over a 5–year period. Condoms and combined oral contraceptives (COC) account for 86.8% of the total cost and the other methods only 13.2%. There are differences in contraceptive use according to women’s age. Short-acting reversible contraceptives (SARC) such as COC, condom and vaginal ring, are most commonly used by younger women. However, SARC are correlated with the highest failure rate, resulting in over €7.2 billion cost, explained by the high number of UP. Long-acting reversible contraceptives (LARC), such as the levonorgestrel-releasing intrauterine system (LNG-IUS20), implant and copper intrauterine devices (IUD), are selected by women over 35 years of age due to user-independent compliance. SARC methods result in a higher cost per woman over 5 years: vaginal ring €2427.8, patch €2402.6, condom €2060.1 and COC €1895.1; while LARC methods are the most economic option per women: LNG-IUS20 €630.4, copper IUD €658.2, LNG-IUS12 €703.8, intramuscular injectable €907.8 and implant €940.5. Conclusions: LARC methods result in lower costs compared with SARC options from the perspectives of the SNHS and women, explained by user-independent compliance, preventing a significant number of UP and its elevated economic burden. An increased LARC methods use could avoid UP events, leading to significant cost-savings for the SNHS.
Publisher
The Journal of Health Economics and Outcomes Research
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference26 articles.
1. Direct costs of unintended pregnancy in Spain;Lete;Eur J Contracept Reprod Heal Care,2015
2. Trends in the use of contraceptive methods and voluntary interruption of pregnancy in the Spanish population during 1997-2007;Dueñas;Contraception,2011
3. Spanish Society of Contraception. Contraception survey 2016. Accessed April 2017. http://sec.es
4. National Statistics Institute (INE). Accessed April 2017. http://www.ine.es/jaxi/Tabla.htm?path=/t20/p278/p01/2016-2066/l0/&file=01001.px&L=0
5. Contraceptive practices of women requesting induced abortion in Spain: A cross-sectional multicentre study;Serrano;Eur J Contracept Reprod Heal Care,2012